Li Zeya, Wang Yingdong, Wu Shanshan, Xiao Jingnan, Guo Lei, Meng Shaoke, Zhong Lei, Ding Huaiyu, Lv Haichen, Zhou Xuchen, Huang Rongchong
Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.
Hellenic J Cardiol. 2023 Jan-Feb;69:9-15. doi: 10.1016/j.hjc.2022.12.001. Epub 2022 Dec 9.
This study aimed to assess the effects of coronary collateral circulation (CCC) on the prognosis of patients with chronic total occlusion (CTO) under different treatment strategies.
We analyzed a total of 1124 patients who were diagnosed with CTO and divided them into groups with good CCC (grade 2 to 3, n = 539) or poor CCC (grade 0 to 1, n = 531). The primary outcome was cardiac death during follow-up; the secondary outcome was major adverse cardiovascular events (MACEs). We also performed subgroup analyses in groups with and without CTO revascularization (CTO-R and CTO-NR, respectively), and sensitivity analyses excluding patients who received failed CTO-PCI to further investigate the effect of CCC.
During a median follow-up duration of 23 months, we did not detect any significant differences between the good CCC group and the poor CCC group in terms of cardiac death (4.2% vs 4.1%; adjusted hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.56-1.83; p = 0.970) and MACEs (23.6% vs 23.2%; adjusted HR, 1.07; 95% CI, 0.84-1.37; p = 0.590). Subgroup analyses according to CTO revascularization showed similar results. In addition, we observed no differences in sensitivity analyses when patients who received failed CTO-PCI were excluded.
Good CCC was not associated with a lower risk of cardiac death or MACEs among patients with CTO, regardless of whether the patients received CTO revascularization treatment.
本研究旨在评估在不同治疗策略下,冠状动脉侧支循环(CCC)对慢性完全闭塞(CTO)患者预后的影响。
我们共分析了1124例被诊断为CTO的患者,并将他们分为CCC良好组(2至3级,n = 539)和CCC不良组(0至1级,n = 531)。主要结局是随访期间的心源性死亡;次要结局是主要不良心血管事件(MACE)。我们还分别在有和没有CTO血运重建的组(分别为CTO-R和CTO-NR)中进行了亚组分析,并进行了敏感性分析,排除了接受CTO-PCI失败的患者,以进一步研究CCC的影响。
在中位随访期23个月期间,我们未发现CCC良好组和CCC不良组在心源性死亡(4.2%对4.1%;调整后的风险比[HR],1.01;95%置信区间[CI],0.56-1.83;p = 0.970)和MACE方面有任何显著差异(23.6%对23.2%;调整后的HR,1.07;95% CI,0.84-1.37;p = 0.590)。根据CTO血运重建进行的亚组分析显示了相似的结果。此外,当排除接受CTO-PCI失败的患者时,我们在敏感性分析中未观察到差异。
无论患者是否接受CTO血运重建治疗,良好的CCC与CTO患者较低的心源性死亡风险或MACE风险均无关。